Clinical trial data is among the most valuable knowledge assets in pharmaceutical development. Each trial represents years of scientific effort and millions in investment. Yet most of that value stays trapped in individual study datasets — locked in study-specific database structures, using study-specific coding decisions, with metadata that is insufficient to support queries across studies. The consequence is that analytical questions that should be answerable from an existing portfolio of trials require either new studies or lengthy manual data harmonisation efforts.
The Study-Specific Data Problem
Clinical data management practices have historically been optimised for individual study delivery — producing clean datasets that satisfy the regulatory submission requirements for that specific study. Cross-study reuse was not a design requirement, and its absence is visible in the data structures that result: endpoint definitions that differ subtly between studies of the same compound, adverse event coding that was performed with different MedDRA versions, eligibility criteria expressed in free text rather than structured logic, and population characteristics described at different levels of granularity. Harmonising these differences post-hoc is expensive and introduces interpretive judgements that are difficult to document and defend.
Ontology-Aligned Standards at the Data Collection Stage
The most effective solution is to establish ontology-aligned data standards before study start, so that cross-study harmonisation is built in rather than retrofitted. This means: defining endpoints using shared ontology concept identifiers so that "overall survival" means the same thing in every study; requiring that eligibility criteria be expressed as structured logical conditions against standardised concept identifiers; using a fixed MedDRA version for adverse event coding within a programme and mapping to successor versions as part of the submission process rather than the analysis process; and capturing patient baseline characteristics against a standardised clinical ontology that supports hierarchical querying.
The Return on Investment
The upfront cost of implementing ontology-aligned data standards — revised CRF design, updated data management specifications, additional data review steps — is real but modest compared to the downstream analytical return. Integrated study databases that share a common ontological reference layer support integrated analyses, subgroup queries across studies, and exposure-response analyses that would otherwise require multi-month data harmonisation programmes. For late-stage development programmes and post-marketing commitments, the ability to query across the full clinical evidence base in structured terms is a strategic capability that compounds in value with every additional study completed.
